-
Agbottah E, de La Fuente C, Nekhai S, Barnett A, Gianella-Borradori A, Pumfery A, Kashanchi F, 2005: Antiviral activity of CYC202 in HIV-1-infected cells[J]. J Biol Chem, 280, 3029-3042. doi: 10.1074/jbc.M406435200
-
Arts EJ, Hazuda DJ (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med 2: a007161
-
Bedini E, Carabellese A, Barone G, Parrilli M, 2005: First synthesis of the beta-D-rhamnosylated trisaccharide repeating unit of the O-antigen from Xanthomonas campestris pv[J]. campestris 8004. J Org Chem, 70, 8064-8070.
-
Cary DC, Peterlin BM, 2018: Natural products and HIV/AIDS[J]. AIDS Res Hum Retroviruses, 34, 31-38. doi: 10.1089/aid.2017.0232
-
Chia YC, Chang FR, Teng CM, Wu YC, 2000: Aristolactams and dioxoaporphines from Fissistigma balansae and Fissistigma oldhamii[J]. J Nat Prod, 63, 1160-1163. doi: 10.1021/np000063v
-
Choi YL, Kim JK, Choi SU, Min YK, Bae MA, Kim BT, Heo JN, 2009: Synthesis of aristolactam analogues and evaluation of their antitumor activity[J]. Bioorg Med Chem Lett, 19, 3036-3040. doi: 10.1016/j.bmcl.2009.04.020
-
Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R, 2016: HIV reservoirs: what, where and how to target them[J]. Nat Rev Microbiol, 14, 55-60. doi: 10.1038/nrmicro.2015.5
-
Clouser CL, Patterson SE, Mansky LM, 2010: Exploiting drug repositioning for discovery of a novel HIV combination therapy[J]. J Virol, 84, 9301-9309. doi: 10.1128/JVI.01006-10
-
Couture A, Deniau E, Grandclaudon P, Rybalko-Rosen H, Leonce S, Pfeiffer B, Renard P, 2002: Synthesis and biological evaluation of aristolactams[J]. Bioorg Med Chem Lett, 12, 3557-3559. doi: 10.1016/S0960-894X(02)00794-1
-
De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH, 1997: Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine[J]. Eur J Biochem, 243, 518-526. doi: 10.1111/j.1432-1033.1997.0518a.x
-
Esposito F, Tintori C, Martini R, Christ F, Debyser Z, Ferrarese R, Cabiddu G, Corona A, Ceresola ER, Calcaterra A, Iovine V, Botta B, Clementi M, Canducci F, Botta M, Tramontano E, 2015: Kuwanon-L as a new allosteric HIV-1 integrase inhibitor: molecular modeling and biological evaluation[J]. ChemBioChem, 16, 2507-2512. doi: 10.1002/cbic.201500385
-
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF, 1997: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy[J]. Science, 278, 1295-1300. doi: 10.1126/science.278.5341.1295
-
Gibson KM, Steiner MC, Kassaye S, Maldarelli F, Grossman Z, Perez-Losada M, Crandall KA, 2019: Corrigendum: a 28-year history of HIV-1 drug resistance and transmission in Washington[J]. DC Front Microbiol, 10, 2590-. doi: 10.3389/fmicb.2019.02590
-
Havlicek L, Hanus J, Vesely J, Leclerc S, Meijer L, Shaw G, Strnad M, 1997: Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds[J]. J Med Chem, 40, 408-412. doi: 10.1021/jm960666x
-
Hoarau C, Couture A, Cornet H, Deniau E, Grandclaudon P, 2001: A concise total synthesis of the azaphenanthrene alkaloid eupolauramine[J]. J Org Chem, 66, 8064-8069. doi: 10.1021/jo0105944
-
Hsu MC, Schutt AD, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ, Volsky DJ, 1991: Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist[J]. Science, 254, 1799-1802. doi: 10.1126/science.1763331
-
Ivanov A, Lin X, Ammosova T, Ilatovskiy AV, Kumari N, Lassiter H, Afangbedji N, Niu X, Petukhov MG, Nekhai S, 2018: HIV-1 Tat phosphorylation on Ser-16 residue modulates HIV-1 transcription[J]. Retrovirology, 15, 39-. doi: 10.1186/s12977-018-0422-5
-
Jayasuriya H, Lingham RB, Graham P, Quamina D, Herranz L, Genilloud O, Gagliardi M, Danzeisen R, Tomassini JE, Zink DL, Guan Z, Singh SB, 2002: Durhamycin A, a potent inhibitor of HIV Tat transactivation[J]. J Nat Prod, 65, 1091-1095. doi: 10.1021/np010642f
-
Kashiwada Y, Hashimoto F, Cosentino LM, Chen CH, Garrett PE, Lee KH, 1996: Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents[J]. J Med Chem, 39, 1016-1017. doi: 10.1021/jm950922q
-
Kashman Y, Gustafson KR, Fuller RW, Cardellina JH 2nd, McMahon JB, Currens MJ, Buckheit RW Jr, Hughes SH, Cragg GM, Boyd MR, 1992: The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree[J]. Calophyllum lanigerum. J Med Chem, 35, 2735-2743. doi: 10.1021/jm00093a004
-
Kim SR, Sung SH, Kang SY, Koo KA, Kim SH, Ma CJ, Lee HS, Park MJ, Kim YC, 2004: Aristolactam BⅡ of Saururus chinensis attenuates glutamate-induced neurotoxicity in rat cortical cultures probably by inhibiting nitric oxide production[J]. Planta Med, 70, 391-396. doi: 10.1055/s-2004-818964
-
Kumar V, Poonam Prasad AK, Parmar VS, 2003: Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities[J]. Nat Prod Rep, 20, 565-583. doi: 10.1039/b303648k
-
Margolis AM, Heverling H, Pham PA, Stolbach A, 2014: A review of the toxicity of HIV medications[J]. J Med Toxicol, 10, 26-39. doi: 10.1007/s13181-013-0325-8
-
Mitsuya H, Broder S, 1987: Strategies for antiviral therapy in AIDS[J]. Nature, 325, 773-778. doi: 10.1038/325773a0
-
Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S, 1985: 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type Ⅲ/lymphadenopathy-associated virus in vitro[J]. Proc Natl Acad Sci USA, 82, 7096-7100. doi: 10.1073/pnas.82.20.7096
-
Mousseau G, Valente S (2012) Strategies to block HIV transcription: focus on small molecule tat inhibitors biology (Basel) 1: 668–697
-
Mousseau G, Clementz MA, Bakeman WN, Nagarsheth N, Cameron M, Shi J, Baran P, Fromentin R, Chomont N, Valente ST, 2012: An analog of the natural steroidal alkaloid cortistatin a potently suppresses Tat-dependent HIV transcription[J]. Cell Host Microbe, 12, 97-108. doi: 10.1016/j.chom.2012.05.016
-
Pang R, Zhang C, Yuan D, Yang M, 2008: Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat-TAR interaction inhibitors[J]. Bioorg Med Chem, 16, 8178-8186. doi: 10.1016/j.bmc.2008.07.043
-
Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D, 1998: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1[J]. J Virol, 72, 2855-2864. doi: 10.1128/JVI.72.4.2855-2864.1998
-
Reddy MC, Jeganmohan M, 2017: Total synthesis of aristolactam alkaloids via synergistic C-H bond activation and dehydro-Diels-Alder reactions[J]. Chem Sci, 8, 4130-4135. doi: 10.1039/C7SC00161D
-
Schang LM, 2002: Cyclin-dependent kinases as cellular targets for antiviral drugs[J]. J Antimicrob Chemother, 50, 779-792. doi: 10.1093/jac/dkf227
-
Shin Y, Choi BS, Kim KC, Kang C, Kim K, Yoon CH, 2017: Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects[J]. J Virol Methods, 249, 1-9. doi: 10.1016/j.jviromet.2017.08.005
-
Shin Y, Kim HG, Park CM, Choi MS, Kim DE, Choi BS, Kim K, Yoon CH, 2020: Identification of novel compounds against Tat-mediated human immunodeficiency virus-1 transcription by high-throughput functional screening assay[J]. Biochem Biophys Res Commun, 523, 368-374. doi: 10.1016/j.bbrc.2019.12.029
-
Tsai IL, Lee FP, Wu CC, Duh CY, Ishikawa T, Chen JJ, Chen YC, Seki H, Chen IS, 2005: New cytotoxic cyclobutanoid amides, a new furanoid lignan and anti-platelet aggregation constituents from Piper arborescens[J]. Planta Med, 71, 535-542. doi: 10.1055/s-2005-864155
-
Wei P, Garber ME, Fang SM, Fischer WH, Jones KA, 1998: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA[J]. Cell, 92, 451-462. doi: 10.1016/S0092-8674(00)80939-3
-
Xu H, Lv M, 2009: Developments of indoles as anti-HIV-1 inhibitors[J]. Curr Pharm Des, 15, 2120-2148. doi: 10.2174/138161209788489168
-
Yao T, Larock RC, 2005: Regio- and stereoselective synthesis of isoindolin-1-ones via electrophilic cyclization[J]. J Org Chem, 70, 1432-1437. doi: 10.1021/jo048007c
-
Yoon CH, Kim SY, Byeon SE, Jeong Y, Lee J, Kim KP, Park J, Bae YS, 2015: p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation[J]. J Virol, 89, 4262-4280. doi: 10.1128/JVI.03087-14
-
Yu X, Lin W, Li J, Yang M, 2004: Synthesis and biological evaluation of novel beta-carboline derivatives as Tat-TAR interaction inhibitors[J]. Bioorg Med Chem Lett, 14, 3127-3130.
-
Yuan D, He M, Pang R, Lin SS, Li Z, Yang M, 2007: The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors[J]. Bioorg Med Chem, 15, 265-272. doi: 10.1016/j.bmc.2006.09.062
-
Zhang YN, Zhong XG, Zheng ZP, Hu XD, Zuo JP, Hu LH, 2007: Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr[J]. Bioorg Med Chem, 15, 988-996. doi: 10.1016/j.bmc.2006.10.034
-
Zhang HJ, Rumschlag-Booms E, Guan YF, Wang DY, Liu KL, Li WF, Nguyen VH, Cuong NM, Soejarto DD, Fong HHS, Rong L (2017) Potent inhibitor of drug-resistant HIV-1 strains identified from the medicinal plant justicia gendarussa. J Nat Prod 80: 1798–1807